Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring primary and isolated coronary artery bypass grafting with cardiopulmonary bypass~Exclusion Criteria:~* history of cardiac surgery~* hematocrit \<33%~* platelet count \<100,000/ml~* allergy to tranexamic acid~* recruited in other studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- group ET (Type: EXPERIMENTAL): Patients receiving early CABG \<=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group EP (Type: PLACEBO_COMPARATOR): Patients receiving early CABG \<= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
- group LT (Type: EXPERIMENTAL): Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group LP (Type: PLACEBO_COMPARATOR): Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with placebo(saline solution)
- group BT (Type: EXPERIMENTAL): Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group BP (Type: PLACEBO_COMPARATOR): Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)

Based on this trial design, predict the completion outcome and termination type (if applicable).